Tyrosine Kinase Inhibitor (tki) - Cancer Science

Relevant Publications

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation.

Issue Release: 2025

Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma.

Issue Release: 2025

Association of Pretreatment Albumin-bilirubin Grade With Hepatotoxicity and Efficacy in EGFR-TKIs Therapy for NSCLC.

Issue Release: 2025

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.

Issue Release: 2024

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.

Issue Release: 2024

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

Issue Release: 2024

Inhibition of Tumoral VISTA to Overcome TKI Resistance via Downregulation of the AKT/mTOR and JAK2/STAT5 Pathways in CML.

Issue Release: 2024

Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.

Issue Release: 2024

Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.

Issue Release: 2024

Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.

Issue Release: 2024

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review.

Issue Release: 2024

Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired 19Del/T790M/-C797S mutation resistance.

Issue Release: 2024

Identification of R776H germline mutations in a patient with multifocal lung adenocarcinoma: A case report and literature review.

Issue Release: 2024

Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma.

Issue Release: 2024

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.

Issue Release: 2024

Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma.

Issue Release: 2024

Bilateral keratitis associated with afatinib therapy.

Issue Release: 2024

How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.

Issue Release: 2024

Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.

Issue Release: 2024

Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.

Issue Release: 2024

What is the Future of Global Cancer Standards?

What are the Treatment Options for Abdominal Pain in Cancer Patients?

Why are Global Collaborations Important in Cancer Research?

How Can Patients and Caregivers Get Started?

Are There Alternatives to PSA Testing?

Why is Planning Ahead Important?

Who Needs a Voice Prosthesis?

What Changes in Vital Signs Should Raise Concern?

What is a Healthcare Proxy?

What are the Therapeutic Strategies Targeting Proliferation?

Tyrosine Kinase Inhibitor (tki) - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics